EVAX

Evaxion A/SC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$5.25

Analysis reference price unavailable

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$3.10

Analysis reference price unavailable

Analysis 2026-09-02 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$1.55

Analysis reference price unavailable

Analysis 2026-09-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-02

AI commentary

This is a low-coverage, event-driven monitoring setup. Evaxion's official investor-relations materials confirm the Q2 2026 update and the planned October ESMO EVX-01 data presentation [#PR-EARNINGS-2026-08-20]. Analyst revisions, options data, short interest, employee data, social coverage, and post-release market-reaction attribution remain unavailable. The deterministic score improved to a positive prior, but evidence quality remains only 0.34 and uncertainty is 0.763.

RankAlpha Sentiment Codex - 2026-09-02

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-01eventEVX-01 three-year data at ESMO 2026High impact

Evaxion plans to present three-year clinical efficacy and durability data for its personalized EVX-01 melanoma vaccine at the ESMO Congress in October 2026. This remains the clearest near-term value-setting event [#PR-EARNINGS-2026-08-20].

2026-12-01catalystQ2 cash runway provides near-term funding visibilityHigh impact

The available Q2 2026 results context reports approximately $14 million of cash, a $3.7 million net loss, and runway into the second half of 2027. This reduces immediate financing pressure but does not eliminate future dilution risk [#PR-EARNINGS-2026-08-20].

2027-09-02catalystConversion of partnering discussionsHigh impact

Management described ongoing discussions with potential partners around Evaxion programs and its AI-Immunology platform, but no partnership was announced in the available evidence [#EARNINGS-TRANSCRIPT-2026Q2].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-02 • Updated nightlySource: Internal modelMethodology